- Home
- CTSO vs BEAT Comparison
CTSO vs BEAT Comparison
Compare CTSO & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- BEAT
- Stock Information
- Founded
- CTSO 1997
- BEAT 2015
- Country
- CTSO United States
- BEAT United States
- Employees
- CTSO N/A
- BEAT N/A
- Industry
- CTSO Medical/Dental Instruments
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CTSO Health Care
- BEAT Technology
- Exchange
- CTSO Nasdaq
- BEAT Nasdaq
- Market Cap
- CTSO 61.3M
- BEAT 55.6M
- IPO Year
- CTSO N/A
- BEAT 2021
- Fundamental
- Price
- CTSO $1.03
- BEAT $1.62
- Analyst Decision
- CTSO Strong Buy
- BEAT Buy
- Analyst Count
- CTSO 3
- BEAT 1
- Target Price
- CTSO $4.67
- BEAT $8.00
- AVG Volume (30 Days)
- CTSO 74.6K
- BEAT 63.1K
- Earning Date
- CTSO 05-08-2025
- BEAT 05-08-2025
- Dividend Yield
- CTSO N/A
- BEAT N/A
- EPS Growth
- CTSO N/A
- BEAT N/A
- EPS
- CTSO N/A
- BEAT N/A
- Revenue
- CTSO $35,594,520.00
- BEAT N/A
- Revenue This Year
- CTSO $18.72
- BEAT N/A
- Revenue Next Year
- CTSO $19.75
- BEAT N/A
- P/E Ratio
- CTSO N/A
- BEAT N/A
- Revenue Growth
- CTSO 14.51
- BEAT N/A
- 52 Week Low
- CTSO $0.70
- BEAT $1.45
- 52 Week High
- CTSO $1.61
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- CTSO 53.19
- BEAT 32.29
- Support Level
- CTSO $0.93
- BEAT $1.57
- Resistance Level
- CTSO $1.07
- BEAT $1.74
- Average True Range (ATR)
- CTSO 0.06
- BEAT 0.14
- MACD
- CTSO 0.01
- BEAT -0.01
- Stochastic Oscillator
- CTSO 71.43
- BEAT 29.17
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.